One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Long-awaited action on rare diseases
doi : 10.1016/S2665-9913(22)00072-8
Volume 4, Issue 4, April 2022, Page e229
Leflunomide in the treatment of psoriatic arthritis
Clementina López-Medina a b, Ruxandra Schiotis b c, Eduardo Collantes-Estévez a b
Strategy lessons from a new clinical trial in psoriatic arthritis
doi : 10.1016/S2665-9913(22)00039-X
Volume 4, Issue 4, April 2022, Pages e231-e232
Women with gout and COVID-19—an unfortunate combination?
doi : 10.1016/S2665-9913(22)00026-1
Volume 4, Issue 4, April 2022, Pages e233-e234
Who will respond to type I interferon receptor blockade in SLE?
Martin Aringer a
COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease
doi : 10.1016/S2665-9913(21)00417-3
Volume 4, Issue 4, April 2022, Pages e241-e243
Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study
doi : 10.1016/S2665-9913(21)00416-1
Volume 4, Issue 4, April 2022, Pages e243-e246
Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies
doi : 10.1016/S2665-9913(22)00032-7
Volume 4, Issue 4, April 2022, Page e247
Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies – Authors' reply
doi : 10.1016/S2665-9913(22)00035-2
Volume 4, Issue 4, April 2022, Pages e247-e248
Correction to Lancet Rheumatol 2022; 4: e262–73
doi : 10.1016/S2665-9913(22)00070-4
Volume 4, Issue 4, April 2022, Page e249
Titilola (Lola) Falasinnu: looking out for the overlooked
doi : 10.1016/S2665-9913(22)00071-6
Volume 4, Issue 4, April 2022, Page e251
Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial
Michelle L M Mulder MD a c, Johanna E Vriezekolk PhD b, Tamara W van Hal MD a c, Lieke M Nieboer MSc a, Nathan den Broeder MSc a, Prof Elke M G J de Jong MD d, Alfons A den Broeder MD a, Prof Frank H J van den Hoogen MD a, Prof Philip S Helliwell MD e, Mark H Wenink MD a
Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study
doi : 10.1016/S2665-9913(22)00008-X
Volume 4, Issue 4, April 2022, Pages e262-e273
Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study
doi : 10.1016/S2665-9913(21)00401-X
Volume 4, Issue 4, April 2022, Pages e274-e281
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials
Prof Eric F Morand MBBS a, Prof Richard A Furie MD b, Prof Ian N Bruce MD c, Edward M Vital MRCP d e, Prof Maria Dall'Era MD f, Emmanuelle Maho PhD g, Lilia Pineda MD h, Raj Tummala MD h
Cognitive dysfunction in systemic lupus erythematosus: how do we advance our understanding?
Sudha Raghunath FRACP a c, Yifat Glikmann-Johnston PhD b, John G Hanly MD d, Prof Eric F Morand FRACP a c, Prof Julie C Stout PhD b, Alberta Hoi FRACP a c
